DeNovaMed
Investment

DeNovaMed's founders used computer-aided drug design to develop a new class of compounds with the potential to treat infections caused by drug-resistant bacteria, or “superbugs.” The company plans to evaluate its best compounds in animal models of infection, with an ultimate goal of bringing to market a truly new antibiotic.

5850/5980 University Ave.
Halifax, NS B3K 6R8
Canada
902.470.7523